Replies to post #19556 on RespireRx Pharmaceuticals Inc (RSPI)

[fearfrost]

Agreed, get some energy! And he never addressed the botched doses, what a let down.

But good news is good news. Congrats to all!

[bladerunner1717]

It looks like COR intends to commercialize CX717 for RD. Stoll mentioned the possibility of patent extensions, but even without extensions he saw a commercial life of about 8 years for CX717 in RD.

He did seem more excited about CX1942 for RD. He mentioned that CX1942 was about a year and a half behind CX717 in terms of development.


Bladerunner

[laker9029]

I did not hear any specifics on the procedural problems at 900mg and 1500mg. The rescue data, in humans, at 2100mg was impressive. I also noted that the curves for 900mg and 1500mg in rat data showed an obvious effect. Roger actually seemed to avoid mentioning a "procedural problem".

The strategy to move ahead with CX717 followed by CX742 makes sense to me, especially since CX742 will be "quickly partnered".

The pipeline and market data were impressive. Overall, I thought it was a great presentation showing lots of promise,both short term (next few weeks!!) and longer term, as well.

Any thoughts on the paramaters and value of a partnership? -- is this $20million or $200million?

L